Following an announcement in October 2022, CIVCO Radiotherapy confirmed that the company would be joining forces with Qfix to create one company with one mission: To Improve Care and Outcomes for Patients and Providers through a Passion for Innovation. The merger of the two companies will provide an improved level of customer services (sales and customer care), new and improved products, and expanded R & D capabilities.
As a result of this news, Oncology Imaging Systems is proud to confirm that it will become the distributor of both CIVCO RT and Qfix products across the UK and Ireland. The announcement was communicated internally in early March 2023 and has been well received by the entire OIS team, whose mission and values strongly align with those of the newly combined company. The OIS team is united by a customer-centric attitude and a patient-first ethos, always putting clinicians and their patients first.
Moving Forward
Xiel Ltd, the existing CIVCO Radiotherapy distributor, will hand over the reins to OIS on the 5th May 2023, making OIS the exclusive distributor of both CIVCO RT and Qfix products from that date. All orders and support enquiries for CIVCO RT products will continue to be processed and responded to by Xiel up until this date. All product warranties will continue to be upheld by the manufacturer.
Xiel is instrumental in supporting OIS with the handover, with all parties involved working closely behind the scenes to ensure a seamless transition. Jack Knight, Managing Director of Xiel, commented, “We have very much enjoyed working with CIVCO RT over the years to serve our radiotherapy customers with high quality equipment ensuring the best level of patient care. We are committed to working closely with OIS during this phase of transition to ensure continuity of supply to the market and most importantly, patients.”
Both Xiel and OIS would like to assure their customers in the UK and Ireland that there will be no break in product availability or after-sales support, regardless of the sales channel or distribution partner through which equipment purchases were made.
“We would like to extend our thanks to Xiel for working together with us to prioritise the needs of the radiotherapy community, clinicians and patients during this transition,” says Steve Imber, Founding Director of OIS. “Maintaining the supply and service continuity that our valued customers have come to expect from us is a core focus for both companies.”
About Qfix
Qfix provides state-of-the-art patient positioning and immobilisation devices to optimise patient outcomes. Known for their superior thermoplastics and revolutionary positioning devices, Qfix specialises in immobilisation products that offer a unique combination of rigidity and ultra-low attenuation.
OIS are proud to have worked in partnership with Qfix since 2004. The team has built a fantastic relationship with Qfix, working closely on development and innovation. The collaboration has allowed OIS to provide radiotherapy centres in the UK and Ireland with high-quality, technology-driven solutions for their patient positioning needs.
About CIVCO RT
CIVCO Radiotherapy is a global provider of radiotherapy solutions focusing on improving outcomes for patients and healthcare providers worldwide through high-quality, innovative, patient-centric radiotherapy solutions.
Founded in 1982, CIVCO has a 40-year track record of designing and manufacturing radiotherapy patient positioning and immobilisation devices. The company has a solid history of innovation and growth, today employing over 100 people worldwide who are committed to improving the patient journey.
Better Together
CIVCO Radiotherapy/Qfix CEO Nat Geissel's statement says that, by combining, the companies will be Better Together. “In particular, we look forward to benefiting from Qfix’s robust internal manufacturing capabilities to accelerate innovation and deliver improved products, faster - all while continuing to provide best-in-class customer care,” states Nat.
As the two companies integrate over the coming months, the OIS team look forward to playing a pivotal role in helping the newly combined company deliver their mission to the highest standard.
Learn more:
Comments